Corient Private Wealth
DTIL icon

Corient Private Wealth’s Precision BioSciences DTIL Stock Holding History

Corient Private Wealth’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
245,058
+101,206
+70% +$712K ﹤0.01% 1419
2026
Q1 		$55.7K Buy
143,852
+133,852
+1,339% +$618K ﹤0.01% 2750
2025
Q4 		$41.6K Hold
10,000
– – ﹤0.01% 2606
2025
Q3 		$55.2K Sell
10,000
-91,206
-90% -$437K ﹤0.01% 2491
2025
Q2 		$425K Buy
+101,206
New +$499K ﹤0.01% 1790
2025
Q1 		– Sell
-20,203
Closed -$77 – 2327
2024
Q4 		$77 Buy
20,203
+6,431
+47% +$47K ﹤0.01% 2354
2024
Q3 		$123K Hold
13,772
– – ﹤0.01% 2300
2024
Q2 		$134K Buy
13,772
+1,891
+16% +$22.3K ﹤0.01% 2178
2024
Q1 		$161K Buy
11,881
+4,297
+57% +$52.6K ﹤0.01% 2132
2023
Q4 		$83K Buy
7,584
+5,279
+229% +$56.9K ﹤0.01% 2170
2023
Q3 		$23.6K Buy
2,305
+14
+0.6% +$215 ﹤0.01% 2107
2023
Q2 		$36.2K Sell
2,291
-14
-0.6% -$320 ﹤0.01% 2035
2023
Q1 		$52.1K Buy
2,305
+1,851
+408% +$61K ﹤0.01% 1936
2022
Q4 		$16.2K Buy
+454
New +$17.9K ﹤0.01% 1672

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Corient Private Wealth's DTIL Position: Q2 2026 in Review

Corient Private Wealth increased its Precision BioSciences (DTIL) stake by 70% in Q2 2026, buying an estimated $712K and bringing the position to 245,058 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Corient Private Wealth first reported a position in DTIL in Q4 2022 and has held it in 14 quarters since. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Corient Private Wealth held 245,058 shares of Precision BioSciences worth $1.93M as of Q2 2026.
  • Corient Private Wealth bought 101,206 Precision BioSciences shares in Q2 2026, an estimated $712K.
  • Precision BioSciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1419 holding.
  • Corient Private Wealth first reported a position in Precision BioSciences in Q4 2022 and has held it in 14 quarters since.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.